v
Search
Advanced

Publications > Journals > Journal of Clinical and Translational Hepatology > Article Full Text

  • Review Article
  • OPEN ACCESS

Fatty Liver Disease and Gut Microbiota: A Comprehensive Update

  • Lyna Campo,
  • Sara Eiseler,
  • Tehilla Apfel and
  • Nikolaos Pyrsopoulos*,
 Author information  Cite
Journal of Clinical and Translational Hepatology   2019;7(1):56-60

doi: 10.14218/JCTH.2018.00008

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in the absence of secondary causes. NAFLD is a multifactorial disease that results from the interaction of genetic predisposition and metabolic, inflammatory and environmental factors. Among these factors, dysregulation of gut microbiome has been linked to the development of fatty liver disease. The microbiome composition can be modified by dietary habits leading to gut microbiome dysbiosis, especially when a diet is rich in saturated fats, animal products and fructose sugars. Different species of bacteria in the gut metabolize nutrients differently, triggering different pathways that contribute to the accumulation of fat within the liver and triggering inflammatory cascades that promote liver damage. In this review, we summarize the current understanding of the roles of gut microbiota in mediating NAFLD development and discuss possible gut microbiota-targeted therapies for NAFLD. We summarize experimental and clinical evidence, and draw conclusions on the therapeutic potential of manipulating gut microbiota to decrease the incidence and prevalence of fatty liver disease.

Keywords

Nonalcoholic fatty liver disease, Gut microbiome, Dysbiosis, Endotoxins, Choline metabolism

Introduction

Nonalcoholic fatty liver disease (NAFLD) includes steatosis without inflammation, nonalcoholic steatohepatitis (NASH) or NASH-induced cirrhosis.1 Linked to the worldwide rise in obesity and metabolic syndrome, NAFLD has become the most common types of chronic liver disease.2 It is most commonly diagnosed by imaging and often confirmed with liver biopsy. Worldwide, NAFLD has a reported prevalence of 4–46%.3 However, the prevalence of NAFLD differs by region.3

Initially, it was thought that liver injury from NAFLD resulted from inflammatory cytokines and adipokines that were stimulated by the gradual accumulation of triglycerides in the liver, leading to mitochondrial dysfunction and oxidative stress, resulting in steatohepatitis and ultimately fibrosis.4,5 More recent studies have shown that gut microbial organisms play an important role in the metabolic regulation of glucose and lipids contributing to the development of metabolic syndrome and NAFLD.4,6

The liver and the gut have an intimate functional and anatomical relationship, as the liver receives approximately 70% (1000–1200 mL/min) of its blood supply from the intestines through the portal circulation.7 The enteric lining of the intestines serves as an immunological barrier, preventing the movement of antigens in the gut from entering the portal circulation.7 Antigens that do cross the barrier are mostly eliminated by the innate immune system, preventing them from reaching the liver and thereafter the systemic circulation.

The gut microbiome comprises all of the microorganisms in the digestive tract. Imbalance of the bacteria found in the gut is known as dysbiosis and can prevent the immunologic barrier in the gut from functioning properly. Dysbiosis has also been associated with the development of chronic metabolic conditions, such as insulin resistance, diabetes, cardiovascular disease, obesity and NAFLD8 Bacteria dysbiosis has been linked to altered energy homeostasis, increased inflammation, and choline and bile acid metabolism, which have all been thought important to the development of NAFLD.8

Dysbiosis also leads to endotoxemia and inflammation of the gut wall and activation of Kupffer cells and hepatic stellate cells.7 This causes the activation of proinflammatory cells via activation of the Toll-like receptors (TLRs) 9 and 4 and the tumor necrosis factor-alpha (TNF-α) receptors, leading to liver injury and inflammation (Fig. 1).8,9 There are multiple animal and human studies that have demonstrated the relationship between the gut microbiome and development of NAFLD3 (Table 1). Studies have also shown that lean individuals with a body mass index less than 25 have a different microbiome composition, when compared to obese individual with a body mass index greater than 3010–12 (Table 1).

Mechanisms of dysbiosis and NAFLD development.
Fig. 1.  Mechanisms of dysbiosis and NAFLD development.

Dysbiosis in the gut results in increased levels of endogenous alcohol, SCFA, fasting-induced adipose factor (also known as Fiaf) and decreased production of the essential nutrient choline, all of which contribute to NAFLD, steatosis, steatohepatitis and ultimately fibrosis or cirrhosis as the process evolves. Dysbiosis also leads to endotoxemia by triggering Kupffer and stellate cells to active Toll-like receptors 9 and 4. This leads to the activation of TNF-α and ultimately NAFLD. Abbreviations: NAFLD, nonalcoholic fatty liver disease; SCFA, short chain fatty acids; TNF-α, tumor necrosis factor-alpha.

Table 1.

Studies on gut microbiome and NAFLD

Type of studySubjectsOutcomeRef
Randomized control trial38 patients total; 16 of the patients were NASH patients and 7 were given probiotic versus 9 usual care group versus 22 controls.NASH patients had lower concentration of Faecalibacterium and Anaerosporobacter. There were higher concentrations of Parabacteroides and Allisonella.11
Cross sectional study63 children total; 16 controls, 25 obese patients and 22 NASH patients.Proteobacteria/Enterobacteriaceae/Escherichia was equally represented in both healthy and obese microbiomes but was higher in NASH.24
Cross sectional study60 patients total; 30 NAFLD patients versus 30 controls.Lactobacillus were higher in NAFLD patients.19
Observational study15 female patients were placed on choline diets and the levels were modified.In patients with low-choline diet there were increased levels of Gammaproteobacteria and Erysipelotrichi bacteria, and fatty liver.35
Randomized controlled trial48 children with NAFLD were treated with VSL#3 versus placebo.VSL#3 supplementation for a total of 4 months improved NAFLD in children.12

The gut microbiome

The gastrointestinal tract has approximately one hundred trillion commensal organisms and contains over 7000 different strains of bacteria.8 The number of bacteria varies based on the location within the gut, increasing from the stomach to the colon. The bacterial composition also depends on age and diet.13 Real-time PCR, microarray, and pyrosequencing have been used to improve the resolution of the microbial biodiversity and quantification of microbial species.11 Most studies have shown a high level of bacteroidetes in the gut microbiota composition. Claesson et al.14 analyzed the composition of intestinal microbiota by pyrosequencing and found that the phylum Bacteroidetes was the predominant species of intestinal microbiota, found in 68% of the individuals studied and accounting for 57% of bacteria in the microbiome. The phylum Firmicutes follows as a close second, accounting for up to 40% of bacteria in many individuals.12 Other bacteria, including Proteobacteria, Actinobacteria, Faecalibacteria, Verrucomicrobia Cyanobacteria, and Lactobacillus are also found at lower levels in the human intestine.12

Microbial composition varies between cohabiting or related individuals. Studies in twins, that are born with a common gut microbiome revealed that the microbiota composition changes over time once a person is exposed to different environmental factors such as food, antibiotics, and infections.15 Multiple studies have shown that obesity can change the composition of the common gut microbiome, leading to dysbiosis.16 However, there is no consensus amongst studies about what the most common microbiota compositional changes are that occur in NALFD and obesity.

Studies have shown that bacteroides is seen at higher levels in lean individuals, whereas Actinobacteria and Firmicutes were found at higher levels in obese individuals.11,17–20 This was supported in a study by Turnbaugh et al.,18 that showed that the transplantation of intestinal bacteria from genetically obese mice to lean mice significantly enhanced the effectiveness of intestinal energy absorption and increased the body weight of the lean mice.18 Similarly, analysis of the gut microbiome in NAFLD patients revealed a lower percentage of Bacteroides and higher levels of Prevotella and Porphyromonas species compared to lean controls.11 Additionally, a change in the ratio between bacteroidetes to firmicutes is often noted in studies in both obese and NAFLD groups.21

A recent meta-analysis by Sze et al.21 re-examined the relationship between gut microbiome and obesity and did not show a significant association between an increased ratio of bacteroides to firmicutes. They did not, however, comment on the relationship of gut microbial and NAFLD specifically.

Lipid metabolism and dysbiosis

Saturated fat accumulation has been found to induce hepatic steatosis by creating changes in the gut microbiome.22 De Wit et al.,22 studied the effect of dietary fat types in the development of obesity, insulin sensitivity, and liver triglyceride levels. Their findings suggest that a high-fat diet including palm oil, which is high in saturated fat, increases steatosis incidence, lowers microbial heterogeneity, and raises the Firmicutes-to-Bacteroidetes ratio, which we noted may be a marker for obesity.22

In another study, Backhead et al.15 demonstrated that microbiome transplantation from conventional mice (mice that obtained a microbiota beginning at birth) to germ-free mice (mice raised in the absence of any microorganisms) produced a 57% increase in total body fat content and a 2.3-fold increase in the content of liver triglycerides in germ-free mice. Real-time polymerase chain reaction assays confirmed that the colonization elevated the liver mRNA levels of two key enzymes for the fatty acid biosynthetic pathway—(acetyl-CoA carboxylase (also known as Acc1) and fatty acid synthase (also known as Fas).15

These lipogenic enzymes increase and activate microbiota by liver carbohydrate response element binding protein (also known as ChREBP) and sterol regulatory element binding protein-1 (also known as SREBP-1), leading to uptake of dietary polysaccharides.4,9,15 These complex carbohydrates are not able to be digested by the gut bacteria and instead undergo fermentation to form inulin, acetate, propionate and butylate.4,7,15 Butylate is used as a substrate by the bacteria in the intestinal mucosa. Acetate and propionate are energy substrates in lipogenesis.7 They can enhance the host energy production in the intestinal tract, thus contributing to the development of obesity and metabolic disease.7

Multiple studies have also shown that gut microbiota promote intestinal absorption of monosaccharides, accelerating de novo hepatic lipogenesis and suppressing fasting-induced adipocyte factor, which results in the accumulation of triglycerides in adipocytes16 and thus contributes to fatty liver development. A study on NASH patients by Vrieze et al.23 showed that insulin sensitivity improved significantly after allogenic/autologous fecal transplant, along with levels of butyrate-producing intestinal microbiota.

Lipoprotein lipase (LPL) is a key regulator of the release of fatty acid from the adipocytes, and heart and muscle cells.13 It has been demonstrated that gut bacteria enhance the storage of triglycerides by suppressing the intestinal expression of LPL inhibitor.13 This suppression occurs through a decrease of the LPL inhibitor Fiaf, the fasting-induced adipose factor, which leads to the subsequent increase in LPL activity in adipocytes, thereby promoting an increase in hepatic lipogenesis and storage of calories supplied by the diet.4,9 This further fuels the development of fatty liver disease by predisposing towards obesity.

Ethanol and NAFLD

Ethanol is a normal by-product of metabolism in the human body. The liver removes ethanol through liver alcohol dehydrogenases, catalases and the microsomal oxidizing system.4 The alcohol hypothesis postulates that increased levels of endogenous ethanol are associated with increased oxidative stress, directly leading to activation of the inflammatory cascade which ultimately causes fatty liver and cirrhosis.4 Zhu et al.24 studied ethanol blood alcohol levels in NASH patients who had not consumed any ethanol-containing beverages and compared the findings to non-NASH patients. The NASH patients were found to have significantly higher levels of blood ethanol levels when compared to obese and lean patients who did not have NASH.22

Interestingly, it is commonly noted that liver biopsies from patients with NASH have similar histology to liver biopsies from patients with alcoholic liver disease, perhaps pointing to a common promoter as the cause of the liver changes. Additionally, increased ethanol levels have been shown to increase gut permeability, which leads to increased lipopolysaccharide levels.4 The mechanism by which increased ethanol levels occur in NAFLD individuals is not fully understood. Some studies have shown that intestinal microflora are the major source of endogenous alcohol.25 However, a single bacterial culprit has not been identified. Escherichia coli is thought to be the primary producer of ethanol, but multiple studies have not found high levels of E. coli in the microbiomes of NAFLD patients.17

Progression of NAFLD

NAFLD progression is presumed to result in part from interactions between the innate immune system and the gut bacteria. This may be due to a mechanism mediated by the inflammasome.26 The inflammasome is a cytoplasmic, multiprotein complex that senses pathogenic bacteria and leads to the activation of an inflammatory response and cellular pyroptosis. Studies have shown that inflammasome deficiency is associated with negative changes in the composition of gut microbiota, and increased fat accumulation in the liver.24,27

Imajo et al.20 used a rat model, with rats fed a high-fat diet to show that obesity induces increased leptin levels, which induces increased levels of multiple profibrogenic factors, such as leading to increased signaling in Kupffer cells. This ultimately results in enhanced response to low-dose lipopolysaccharides, a bacterial endotoxin, leading to the liver inflammation and fibrosis as seen in NASH.20 It is therefore possible that a bacteria-mediated mechanism underlies the progression from simple fatty liver to NASH in humans as well.

Small intestinal bacterial overgrowth (SIBO) and the microbiome

Sebate et al.28 showed a relationship between SIBO, obesity and hepatic steatosis. They measured SIBO by hydrogen breath test concentrations, as a surrogate marker for bacterial concentration, and compared the levels in obese and lean individuals. It was determined that the prevalence of bacterial overgrowth is higher in obese patients than in lean controls and is associated with hepatic steatosis.26 In other studies, patients with SIBO had increased expression of TLR4 and increased release of interleukin-8, which is associated with NAFLD.29 Bacterial overgrowth has also been shown to increase intestinal permeability and promoted bacterial translocation contribute to the progression of liver diseases.30,31

Fructose and the gut microbiome

Dietary fructose intake has also been associated with NAFLD.4 Several studies in mice have shown that dietary fructose induces fatty liver and leads to activation of TLR4 and TLR8, which promote hepatic steatosis.32 Animals fed with a high-fructose diet were found to have an increase in the number of macrophages and increased expression of Toll-like receptors. These factors increase the production of endotoxins by Gram-negative bacteria and lipopolysaccharides, thereby promoting inflammation and hepatic fibrosis.4 This was mainly exhibited in patients with intestinal inflammation or portal hypertension.4

Choline deficiency

The intestinal microbiome also plays a role in the regulation of dietary choline and the anaerobic degradation of choline.33 Low-choline diets have been shown to be associated with NAFLD development.30 Choline levels appear to affect the gut microbiota composition. Choline deficiency leads to an increase in the levels of the Gram-negative bacteria Gammaproteobacteria and Erysipelotrichi. The presence of these species has been associated with increases in fat content in the liver.32 Furthermore, as we noted before, Gram-negative bacteria contain lipopolysaccharides which promote chronic inflammation, metabolic dysfunction, insulin resistance, and diabetes.13,34

In one study, mice that were bred to have a genetic predisposition to insulin resistance and NAFLD were fed a high-fat diet. This led to a change in the gut microbiota and in lower levels of choline.32 Spencer et al.35 demonstrated that a similar relationship between fatty liver and choline exists in humans. They observed 15 women in the hospital who were fed a low-choline diet for 42 days. Sequencing of their gut microbiota during the diet identified two classes of bacteria, Firmicutes/Erysipelotrichi and Proteobacteria/Gammaproteobacteri, both of which were associated with decreased choline production. Importantly, the study subjects were found to have increased hepatic steatosis at the end of the study.35

NAFLD prevention

The current gold standard for the management of NAFLD is weight loss and minimizing metabolic risk factors.19 Data suggest that diet is the most important intervention to target NAFLD and NASH.19 A reduction in body weight of only 5% can improve steatosis and a reduction of 10% can improve steatohepatitis.36 However, many patients struggle to adhere to the recommended lifestyle modifications.1 Many interventions have been studied which could be beneficial for the management of NAFLD37 Weight loss medications, such as ursodeoxycholic acid, thiazolidinedione, polyunsaturated fatty acids, metformin, lipid-lowering drugs and the antioxidant vitamins E and C treatments, have been assessed as treatment options for the management of NAFLD.1 However, the majority of the trials have been of short duration and did not include histological endpoints.1

The PIVENS trial was a large randomized controlled trial of vitamin E versus pioglitazone (a diabetic medication) for 96 weeks in nondiabetic NASH patients.38 A significant improvement in hepatic steatosis and lobular inflammation was demonstrated by both treatments, but neither had a significant effect on hepatic fibrosis scores.38 Guidelines suggest that in nondiabetic patients with biopsy proven NASH, the use of vitamin E is reasonable at a dose of 800 IU/day despite the reported inability to observe an effect on hepatic fibrosis scores.1,38 However, until further data supports its effectiveness, vitamin E should not be considered a standard treatment of NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis.1,38 Larger randomized controlled trials focusing on histological endpoints are necessary to precisely assess the efficacy of current treatment options for NASH.1

The integrity of the gut microbiota depends in part on diet.39 “Plant-based diets” rich in vegetables, grains, fruits, and legumes, compared to “animal-based diets” composed of cheese, egg and meats, have demonstrated significant effects on gut bacteria composition.39 An animal-based diet promotes gut microbiota to increase the production of deoxycholic acid, a precursor to bile acids, and branched-chain fatty acids. Also, the expression of genes for the degradation of polycyclic aromatic hydrocarbons (which are carcinogenic compounds), vitamin biosynthesis and b-lactamase are increased in individuals on an animal-based diet.39 Fructose and saturated fat are more likely to stimulate hepatic lipid accumulation and progression to NASH.39 In mice, high-fructose diet stimulates gut-derived portal endotoxemia, leading to liver steatosis through the activation of TLR4 and TNF-α.39,40 Therefore, recommendations that include promoting diets low in saturated fats and fructose may protect against the development of NAFLD.

Supplements that are sold over the counter, such as probiotics (commensal bacteria in pill form) and prebiotics (chemicals that induce growth or activity of “good bacteria”), have been proposed as possible treatments for gut microbiome dysbiosis.27 Several studies have evaluated probiotics and prebiotics in animal and human models, but due to the diversity of product manufacturing worldwide, there is no standardized dose nor a clear understanding of the treatment duration.40 Additionally, there has not been sufficient studies specifically looking at prebiotics and probiotics and the development or treatment of NAFLD to make firm recommendations for or against their use.41,42 Of the available products on the market, lactobacillus has been the best studied supplement in animal models.43 One animal study found that after 8 weeks of oral administration of Lactobacillus rhamnosus there was a reduction in liver steatosis in diet-induced obese mice, confirmed by liver biopsies.33 In a different study, mice fed with a high-fructose diet and then treated with L. acidophilus and L. casei showed a delayed onset of glucose intolerance, reduced insulin levels, and improved steatosis.33 Therefore, further studies of Lactobacillus in human subjects is warranted.

Conclusions

NAFLD is a multifactorial disease that results from the interaction of genetic predisposition, and metabolic, inflammatory and environmental factors which influence the composition of the gut microbiome.4,7 The microbiome composition can be modified by dietary intake, leading to gut microbiome dysbiosis, especially when these diets are rich in saturated fats, fructose, and animal-based foods. Studies have shown that lean and obese individuals have different types of bacteria in their microbiome.4,7,8 This change seems to trigger the activation of inflammatory pathways that lead to progression of NAFLD.

A recent meta-analysis was published by Sze et al.,36 which examined the relationship between gut microbiome and obesity, did not find an association between obesity and the presence or absence of bacteroidetes and firmicutes in the microbiome. This lack of an association underscores the necessity for further investigation into the relationship between the microbiome and NAFLD independent of obesity. There are many mechanisms that link the gut microbiome with the development of NAFLD which may offer potential targets for further investigation and novel therapeutic interventions, such as targeting the pathways involved with choline metabolism and inflammation.

Abbreviations

LPL: 

lipoprotein lipase

NAFLD: 

nonalcoholic fatty liver disease

NASH: 

nonalcoholic steatohepatitis

SIBO: 

small intestinal bacterial overgrowth

TLRs: 

toll-like receptors

TNF: 

tumor necrosis factor

Declarations

Conflict of interest

Nikolaos Pyrsopoulos declares separate research grants from Gilead Sciences, Intercept, Shire, Genfit, Prometheus, Conatus. The other authors have no conflict of interests related to this publication.

Authors’ contributions

All authors contributed equally to this paper in conception and design of the literature review and analysis as well as in drafting, critical revision, editing, and final approval of the final version (LC, SE, TA, NP).

References

  1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357 View Article
  2. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627-636 View Article
  3. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20:205-214 View Article
  4. Lau E, Carvalho D, Freitas P. Gut microbiota: Association with NAFLD and metabolic disturbances. Biomed Res Int 2015;2015:979515 View Article
  5. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71-83 View Article
  6. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011;5:71-86 View Article
  7. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, et al. Gut—liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471-476 View Article
  8. Boursier J, Diehl AM. Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis 2016;20:263-275 View Article
  9. He X, Ji G, Jia W, Li H. Gut microbiota and nonalcoholic fatty liver disease: Insights on mechanism and application of metabolomics. Int J Mol Sci 2016;17:300 View Article
  10. Duranti S, Ferrario C, van Sinderen D, Ventura M, Turroni F. Obesity and microbiota: an example of an intricate relationship. Genes Nutr 2017;12:18 View Article
  11. Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One 2013;8:e62885 View Article
  12. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014;39:1276-1285 View Article
  13. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015;21:1691-1702 View Article
  14. Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011;108(Suppl 1):4586-4591 View Article
  15. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-15723 View Article
  16. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904 View Article
  17. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-1023 View Article
  18. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031 View Article
  19. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868-875.e3 View Article
  20. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012;16:44-54 View Article
  21. Sze MA, Schloss PD. Looking for a signal in the noise: Revisiting obesity and the microbiome. MBio 2016;7:e01018-e01016 View Article
  22. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 2012;303:G589-G599 View Article
  23. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-916.e7 View Article
  24. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609 View Article
  25. Sarkola T, Eriksson CJ. Effect of 4-methylpyrazole on endogenous plasma ethanol and methanol levels in humans. Alcohol Clin Exp Res 2001;25:513-516 View Article
  26. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-185 View Article
  27. Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun 2013;46:66-73 View Article
  28. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18:371-377 View Article
  29. Shanab AA, Scully P, Crosbie O, Buckley M, O’Mahony L, Shanahan F, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-1534 View Article
  30. Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012;57:1932-1941 View Article
  31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211 View Article
  32. Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012;107:1727-1738 View Article
  33. Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci USA 2012;109:21307-21312 View Article
  34. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006;103:12511-12516 View Article
  35. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-986 View Article
  36. Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, et al. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?. Hepat Mon 2013;13:e15227 View Article
  37. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104 View Article
  38. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685 View Article
  39. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-563 View Article
  40. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983-992 View Article
  41. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013;12:357-363
  42. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol 2015;10:889-902 View Article
  43. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011;22:699-711 View Article
Copyright © 2019 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Journal of Clinical and Translational Hepatology
  • pISSN 2225-0719
  • eISSN 2310-8819

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2732196
  • Visits today : 2144
Back to Top

Fatty Liver Disease and Gut Microbiota: A Comprehensive Update

Lyna Campo, Sara Eiseler, Tehilla Apfel, Nikolaos Pyrsopoulos
  • Reset Zoom
  • Download TIFF